二叶式主动脉瓣狭窄:Medicare受益者中经导管与外科主动脉瓣置换术的全国三年结局
本研究利用美国联邦医疗保险(Medicare)数据,比较了6450例65岁以上二叶式主动脉瓣狭窄患者接受经导管主动脉瓣置换术(n=2679)或孤立外科主动脉瓣置换术(n=3771)的3年结局,倾向性评分匹配后各797对。匹配后,经导管组术后6个月内死亡风险与外科组相似(HR 1.08,95%CI 0.67-1.69),但6个月至3年死亡风险更高(HR 2.16,95%CI 1.22-3.83);心衰再入院风险在6个月内更低(HR 0.51,95%CI 0.31-0.87),6个月至3年更高(HR 4.78,95%CI 2.21-10.36);3年主动脉瓣再干预和卒中风险相似。作者认为需要随机对照数据来指导治疗选择。
要点
- 匹配后经导管组6个月至3年死亡风险高于外科组(HR 2.16,95%CI 1.22-3.83)。
- 匹配后经导管组6个月内死亡风险与外科组相似(HR 1.08,95%CI 0.67-1.69)。
- 匹配后经导管组心衰再入院风险6个月内更低(HR 0.51),6个月至3年更高(HR 4.78)。
核心结论
- 在因二叶式主动脉瓣狭窄接受经导管或外科主动脉瓣置换术的匹配Medicare受益者中,经导管术后3年死亡率更高。
- 但经导管主动脉瓣置换术在术后6个月内死亡风险与外科手术相似,且心衰再入院风险更低。
- 作者认为需要随机对照比较数据来最好地指导治疗选择。
研究设计与样本
- 利用美国联邦医疗保险(Medicare)数据识别2012年至2019年因二叶式主动脉瓣狭窄接受孤立外科主动脉瓣置换术(n=3771)或经导管主动脉瓣置换术(n=2679)的6450例患者。
- 采用倾向性评分匹配,匹配21项基线特征(包括衰弱),生成797对匹配患者。
主要发现
- 未匹配的经导管组患者年龄大于外科组(78岁 vs 70岁),合并症和衰弱更多(所有P < .001)。
- 匹配后,经导管组术后6个月内死亡风险与外科组相似(HR 1.08,95%CI 0.67-1.69),但6个月至3年死亡风险更高(HR 2.16,95%CI 1.22-3.83)。
- 匹配后,经导管组6个月内因心衰再入院风险低于外科组(HR 0.51,95%CI 0.31-0.87),但6个月至3年风险更高(HR 4.78,95%CI 2.21-10.36)。
- 匹配后,3年主动脉瓣再干预风险(HR 1.03,95%CI 0.30-3.56)和卒中风险(HR 1.21,95%CI 0.75-1.96)在两组间相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需要随机对照比较数据来最好地指导治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Randomized trials of transcatheter versus surgical aortic valve replacements have excluded bicuspid anatomy. We compared 3-year outcomes of transcatheter aortic valve replacement versus surgical aortic valve replacement in patients aged more than 65 years with bicuspid aortic stenosis. METHODS: The Centers for Medicare and Medicaid data were used to identify 6450 patients undergoing isolated surgical aortic valve replacement (n = 3771) or transcatheter aortic valve replacement (n = 2679) for bicuspid aortic stenosis (2012-2019). Propensity score matching with 21 baseline characteristics including frailty created 797 pairs. RESULTS: Unmatched patients undergoing transcatheter aortic valve replacement were older than patients undergoing surgical aortic valve replacement (78 vs 70 years), with more comorbidities and frailty (all P < .001). After matching, transcatheter aortic valve replacement was associated with a similar mortality risk compared with surgical aortic valve replacement within the first 6 months (hazard ratio [HR], 1.08, 95% CI, 0.67-1.69) but a higher mortality risk between 6 months and 3 years (HR, 2.16, 95% CI, 1.22-3.83). Additionally, transcatheter aortic valve replacement was associated with a lower risk of heart failure readmissions before 6 months (HR, 0.51, 95% CI, 0.31-0.87) but a higher risk between 6 months and 3 years (HR, 4.78, 95% CI, 2.21-10.36). The 3-year risks of aortic valve reintervention (HR, 1.03, 95% CI, 0.30-3.56) and stroke (HR, 1.21, 95% CI, 0.75-1.96) were similar. CONCLUSIONS: Among matched Medicare beneficiaries undergoing transcatheter aortic valve replacement or surgical aortic valve replacement for bicuspid aortic stenosis, 3-year mortality was higher after transcatheter aortic valve replacement. However, transcatheter aortic valve replacement was associated with a similar risk of mortality and a lower risk of heart failure readmissions during the first 6 months after the intervention. Randomized comparative data are needed to best inform treatment choice.
引用
- Chen Q, Malas J, Megna D, et al. Bicuspid aortic stenosis: National three-year outcomes of transcatheter versus surgical aortic valve replacement among Medicare beneficiaries. J Thorac Cardiovasc Surg. 2023. PMID: 38065520. doi:10.1016/j.jtcvs.2023.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。